Krystal Biotech Inc Cash Flow-to-Debt Ratio
Krystal Biotech Inc cash flow-to-debt ratio. Krystal Biotech Inc (KRYS) has a Cash Flow-to-Debt Ratio of 0.53x as of June 2026, meaning its operating cash flow of $74.79 Million could theoretically repay 1% of its total liabilities ($141.52 Million) in one year. Check earnings quality score of Krystal Biotech Inc to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Krystal Biotech Inc (2016–2025)
Cash flow-to-debt ratio of Krystal Biotech Inc from 2016 to 2025. Historical debt coverage capacity for Krystal Biotech Inc across 10 annual periods. Check cash flow reinvestment rate of Krystal Biotech Inc to assess the company's total reinvestment commitment from operating cash flow.
Krystal Biotech Inc Cash Flow-to-Debt Ratio by Year (2016–2025)
Krystal Biotech Inc cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for Krystal Biotech Inc. For the full cash flow conversion analysis, see KRYS cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 1.76x | $200.87 Million | $114.23 Million | ▲ +55.9% |
| 2024 | 1.13x | $123.42 Million | $109.46 Million | ▲ +150.4% |
| 2023 | -2.24x | $-88.80 Million | $39.71 Million | ▲ +19.5% |
| 2022 | -2.78x | $-100.57 Million | $36.22 Million | ▼ -89.5% |
| 2021 | -1.47x | $-47.94 Million | $32.72 Million | ▼ -5.4% |
| 2020 | -1.39x | $-26.08 Million | $18.76 Million | ▲ +54.6% |
| 2019 | -3.06x | $-18.71 Million | $6.11 Million | ▲ +6.3% |
| 2018 | -3.27x | $-9.45 Million | $2.89 Million | ▲ +46.2% |
| 2017 | -6.08x | $-3.89 Million | $640.00K | ▼ -777.6% |
| 2016 | -0.69x | $-1.31 Million | $1.89 Million | — |